Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23460649 | 0.86 | ELANE (0.47) | ELANEKDM4EALDH1A1 | |
| SCHEMBL6245424 | 0.86 | ELANE (0.49) | ELANEKDM4EALDH1A1CNR2 | |
| SCHEMBL5729023 | 0.85 | ELANE (0.52) | ELANEMEN1KMT2ACNR2 | |
| SCHEMBL30765994 | 0.84 | ELANE (0.46) | ELANEKDM4EALDH1A1 | |
| SCHEMBL6242996 | 0.83 | NPC1 (0.49) | ELANEKDM4EALDH1A1 | |
| SCHEMBL5728832 | 0.82 | ELANE (0.46) | ELANEMEN1KMT2ACNR2 | |
| SCHEMBL6239384 | 0.82 | RAB9A (0.48) | ELANEMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL7953847 | 0.80 | ELANE (0.53) | ELANECNR2 | |
| SCHEMBL5728831 | 0.80 | ELANE (0.42) | ELANEMEN1KMT2A | |
| SCHEMBL30765554 | 0.80 | KDM4E (0.44) | ELANEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | AJINOMOTO CO., INC. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-20050165234-A1 | Process for preparing pyrimidine compound | AJINOMOTO CO. INC (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1553090-A1 | PROCESS FOR PRODUCING PYRIMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1529778-A1 | Production method of pyrimidine derivative, intermediate therefor | Ajinomoto Co., Inc. (JP) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165234-A1 | Process for preparing pyrimidine compound | SERPINB1, CMA1, CTRC | ELANE 27/4885MEN1 906/4885KMT2A 2756/4885 |
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | DPYD, WEE1, DCXR | ELANE 4520/4885MEN1 1538/4885KMT2A 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.